Att A _ RFP 72117 - Offeror Capabilities and Specimens.xlsx
XLSX spreadsheet 27 KB Posted
- Solicitation number
- 75D301-22-R-72117
About this file
This document contains a request for proposal for a Centers for Disease Control and Prevention contract. The CDC requires contracts for a repeat serologic survey using convenience samples collected from commercial laboratories across the United States to estimate the proportion of people infected with or vaccinated for SARS-CoV-2 over time nationally and by location and demographic. Offerors will identify excess blood specimens from non-COVID diagnostic or antibody testing from all 50 states, Washington D.C. and Puerto Rico for monthly collection and testing for qualitative SARS-CoV-2 nucleocapsid antibodies and quantitative IgG anti-spike antibodies. Offerors will collect and test specimens using CLIA-approved or EUA-approved ELISA and COVID-19 IgG and/or IgM serological assays and reflexive microneutralization testing for seropositive specimens. Offerors will provide the CDC with data reports after every 8-week collection period and a final report at the end of the 11-month base period contract with a 12-month option. Questions are due by January 6, 2022 and proposals are due January 24, 2022 to the CDC Office of Acquisition Services.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Att B (amended) _ Task Deliverables Table.xlsx | XLSX spreadsheet | |
| Att C (amended) _ Pricing Table.xlsx | XLSX spreadsheet | |
| Responses to Vendor QA - Att D_Question and Answer Template.xlsx | XLSX spreadsheet | |
| Solicitation Amendment _ Sec. D PWS - RFP 75D301-22-R-72117.docx | DOCX document | |
| RFP 75301-22-R-72117 - MASS-C Serology.doc | DOC document | |
| Att C _ RFP 72117 - Pricing Table.xlsx | XLSX spreadsheet | |
| Att D _ RFP 72117 - Question and Answer Template.xlsx | XLSX spreadsheet | |
| Att B _ RFP 72117 - Task Deliverables Table.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Proposal Responses
| Each offeror should complete and include the below table and subsequent worksheets with their proposal. | ||
| ID | Question | Answer |
| A.1 | How many total specimens from each US state (+ DC and Puerto Rico), stratified by age group, do you typically accumulate over a one week period that could be used in this study? | |
| A.2 | Provide aggregated, available information on the specimens referenced in Question 1 in the below worksheet tab labeled "A.3". | |
| B.1 | How many total specimens from each US state (+ DC and Puerto Rico), stratfied by age group, do you typically accumulate overan eight week period that could be used in this study? | |
| B.2 | Provide aggregated, available information on the specimens referenced in Question 1 in the below worksheet tab labeled "B.3". | |
| C | Please describe if and how you can monitor and adjust for geographic representativeness of specimens selected for testing within a jurisdiction | |
| D.1 | Will you provide sample results and metadata information as both Excel and .CSV file types? | |
| D.2 | Which of the requested variables do you anticipate limitations in your availability to provide in at least 50% of results submitted [Race and ethnicity; 5-digit zip code of patient residence (provider zip code if not available); name of the original laboratory test (e.g. basic metabolic panel, lipid panel);ICD10 diagnosis associated with the original laboratory test; Results (including collection date) of any previous COVID-19 testing on the same patient, including previous PCR testing for SARS-CoV-2 infection or previous testing for SARS-CoV-2 antibodies (antibody assay type should be included, if available); Information on if the specimen came from an outpatient or inpatient facility; Information on payer by category (e.g., private insurer/HMO, Medicaid, Medicare, self-pay, military health system); Unique patient identifier to allow for deduplication of sample results from the same patient in the same round] | |
| E | Do you have any relevant partnerships with organizations serving pediatric populations or other ideas for how to optimize the number of pediatric specimens for testing? | |
| F | How many specimens can you test under Task Area 1 every 8 weeks? | |
| G | How many specimens can you test under Task Area 2 every 8 weeks? | |
| H | Please addend a table of how many lab locations or specimen collection sites you have in each jurisdiction you are applying to cover, by county. Offeror(s) may use the format most convenient to them to convey this information. |
A.3
| With reference to Questions A.1 in "Proposal Responses", provide any of the below information readily available: | ||||
| Jurisdiction (50 states, DC, Puerto Rico) | Estimated # of available specimens (per typical week) | |||
| People aged 0-11 yrs | People aged 12-17 yrs | |||
| Existing labs | Via subcontract | Existing labs | Via subcontract |
B.3
| With reference to Questions B.1 in "Proposal Responses", provide any of the below information readily available: | ||||
| Jurisdiction (50 states, DC, Puerto Rico) | Estimated # of available specimens (per 8 weeks) | |||
| People aged 0-11 yrs | People aged 12-17 yrs | |||
| Existing labs | Via subcontract | Existing labs | Via subcontract |
File details come from the government source that posted it. Updated .